Stockscreener 앱 받기
6.47
0.31%
-0.02
전일 마감가:
$6.49
열려 있는:
$6.49
하루 거래량:
8,227
Relative Volume:
0.76
시가총액:
$464.94M
수익:
$510.62M
순이익/손실:
$110.37M
주가수익비율:
6.883
EPS:
0.94
순현금흐름:
$423.23M
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$5.73
$8.75
Sinovac Biotech, Ltd Stock (SVA) Company Profile
명칭
Sinovac Biotech, Ltd
부문
산업
전화
-
주소
-
Compare SVA vs
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVA
Sinovac Biotech, Ltd
|
6.47 | 464.94M | 510.62M | 110.37M | 423.23M | 0.94 |
Sinovac Biotech, Ltd 주식(SVA)의 최신 뉴스
Licensable picture: A technician puts a bottle of H1N1 flu virus into a transfer cabinet during preparations to produce vaccines for the flu virus at a lab in Wuhan - reutersconnect.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its OfficersSVA - TMX Newsfile
Licensable picture: Technician works in inoculation area of Sinovac Biotech Ltd. during production of a vaccine for the H1N1 flu virus in Beijing - reutersconnect.com
Sinovac Biotech Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
1Globe Capital Deadline Alert - TMX Newsfile
Sinovac Biotech, Ltd. Revenue Breakdown – NASDAQ:SVA - TradingView
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend - Via TT
Price to book forward of Sinovac Biotech, Ltd. – NASDAQ:SVA - TradingView
Sinovac Biotech LtdADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Sinovac Biotech LtdADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Enterprise value to EBIT forward of Sinovac Biotech, Ltd. – NASDAQ:SVA - TradingView
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements - Via TT
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements - STT Info
Sinovac faces delisting after missing 2025 annual report filing - Investing.com
Chancery Sends Sinovac Biotech Suit To Antigua And Barbuda - Law360
Sinovac Controlling Shareholders Escape Investor Disclosure Suit - Bloomberg Law News
Sinovac Wins Nasdaq Reprieve as Governance Fight Drags On - Caixin Global
Sinovac's inactivated hepatitis A vaccine wins contract in Oman - China Daily
Chinese firm Sinovac to supply vaccine to Chile ahead of flu season - scmp.com
Sinovac receives second Nasdaq non-compliance notice - Investing.com
Antigua court sets Sinovac board until 2026 trial over disputed meeting - Investing.com
Sinovac faces Nasdaq delisting over delayed annual report filing - Investing.com
Sinovac expands flu vaccine age range to 6 months and older - China Daily
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment - Yahoo Finance
Sinovac shareholders push for payment of declared $19 dividend - Investing.com
BreakingviewsCOMMENTARY: Biotech nears cure for Chinese corporate epidemic - Reuters
Sinovac Biotech, Ltd (SVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):